This blocks protein translation and induces cell apoptosis.[34] The FDA has already approved this agent for the treatment of CD25+ cutaneous T-cell lymphoma and is currently being evaluated for the treatment of psoriasis.[35] The most recent study has been a phase II multicenter, randomized controlled trial in which 35 patients with severe plaque psoriasis were placed on lower dosing regimens of 0.5, 1.5, or 5 mg/kg of DAB IL-2 administered by IV infusion for 3 consecutive days every other week for 8 weeks. This evidence concerns the gene IL2RA and psoriasis.